While AI technology in China’s healthcare sector is advancing to offer reliable solutions, its potential to revolutionize medicine remains uncertain. The future impact will hinge on how stakeholders navigate the balance between opportunities and risks. In a recent report, China’s National Healthcare Security Administration officially categorized “AI-assisted diagnosis” as part of pathological diagnosis, integrating it into the pricing structure for diagnostic services.
Behind the strides in AI innovation, unresolved legal and ethical issues loom large, including concerns about data compliance, algorithm governance, and the scope of medical practice. Questions persist on how AI can effectively connect laboratory research with clinical applications and how companies can harness their technological capabilities within regulatory boundaries. Alan Zhou, from Global Law Office, notes that healthcare stands out as a sector where AI has made tangible progress and is expanding.
Zhou points out that Chinese AI healthcare firms are concentrating on four key areas: clinical decision support, medical imaging, health management, and patient-oriented services, and drug discovery. These strategic focuses aim to enhance diagnostic accuracy, streamline health management, and steer clear of high-risk medical domains, presenting a cautious approach to implementation. Compliance with data protection regulations is deemed essential for survival in the AI healthcare landscape.
Data sourcing and its legality pose significant challenges, according to Zhou. The development and application of AI technologies rely heavily on extensive data sets for training, particularly in medical and pharmaceutical contexts where patient and trial participant data are sensitive. As technology evolves rapidly, the need for data intensifies, prompting stricter regulatory measures centered on informed consent under the Personal Information Protection Law.
